Metastatic Lung Cancer Responded Completely After a Change in Immunotherapy

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: TTF-1-positive; napsin-positive; PD-L1 0%; high tumour mutational burden; no actionable mutations

Metastatic Site: bone (left iliac bone, acetabulum and thoracic…

After progression on nivolumab, atezolizumab produced a complete response by the 6-month scan; after 35 cycles, the response remained sustained, he was alive and well, and no immune-related adverse effects were documented.

PubMed CentralRead more →

Lung cancer response to pembrolizumab complicated by severe kidney injury

Patient Info: Anonymized, Male, 70+ | Stage IV

The lung tumor had decreased after 5 pembrolizumab courses and had not progressed again by hospital discharge. The kidney complication required temporary dialysis but resolved, with creatinine 0.91 mg/dL at 8-month follow-up.

PubMed CentralRead more →

Pleomorphic lung cancer responding to pembrolizumab plus chemotherapy

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: PD-L1 tumor proportion score >75%; EGFR negative; ROS1 negative; ALK fusion negative

Metastatic Site: right 8th rib, left adrenal gland

His general condition improved as the tumors shrank, and he remained well 7 months after diagnosis with maintenance pembrolizumab planned.

PubMed CentralRead more →

Multifocal stage IIIA lung adenocarcinoma responding to nivolumab

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: CK7-positive; TTF-1-positive; napsin-A-positive; PD-L1 85% positive.

The biopsied lung nodule nearly resolved after four nivolumab cycles, and the remaining pulmonary nodules were stable at 24 months.

PubMed CentralRead more →

Nivolumab-related adrenal failure during treatment for metastatic lung cancer

Patient Info: Anonymized, Female, 60s | Stage IV

Metastatic Site: brain (left cerebellum)

Her confusion, gastrointestinal symptoms, and hyponatremia improved after glucocorticoid and mineralocorticoid replacement, and she was discharged on ongoing hormone replacement.

PubMed CentralRead more →

Stage IV Non-Small Cell Lung Cancer: Donna's Patient Story

Patient Info: Donna Fernandez, Female, 50s | Stage IV

While receiving nivolumab on a Phase III trial, Donna’s tumors remained present but stopped growing, and she was able to return to an active daily life.

Stage III Non-Small Cell Lung Cancer: Renee's Patient Story

Patient Info: Renee Shine, Female, 60s | Stage III

Renee’s tumor responded to pembrolizumab, and she remained on treatment through the clinical trial while describing herself as thriving.

Long-Term Nivolumab Response With Thyroid and Adrenal Side Effects

Patient Info: Anonymized, Male, 50s | Stage IV

Nivolumab remained ongoing at course 82, tumor burden had fallen to one-fifth of baseline, and no disease progression was documented.

PubMed CentralRead more →

Nivolumab-Related Myocarditis and Heart Block in Metastatic Lung Cancer

Patient Info: Anonymized, Male, 70+ | Stage IV

Metastatic Site: left adrenal gland

He stabilized after high-dose steroids and pacemaker implantation after nivolumab was permanently stopped.

PubMed CentralRead more →

Pembrolizumab Produced a Complete Response but Multiple Immune Side Effects

Patient Info: Anonymized, Female, 70+

Biomarkers: PD-L1 expression 100%. Seronegative for acetylcholine-receptor and listed paraneoplastic antibodies during myasthenia-gravis evaluation.

Imaging showed a complete oncologic response that persisted for at least six months after pembrolizumab stopped, while the immune complications resolved after intensive treatment.

PubMed CentralRead more →

Hormone Problems During Nivolumab Treatment for Advanced Lung Cancer

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR/ALK/ROS1/BRAF wild type

Metastatic Site: abdominal wall|brain

She was living with Stage IVA lung cancer after about 1 year of nivolumab. Thyroid levels normalized after levothyroxine adjustment, and continued endocrine monitoring was planned for treatment-related pituitary dysfunction.

PubMed CentralRead more →

Lung Cancer Treatment Complicated by Atezolizumab-Related Pneumonitis

Patient Info: Anonymized, Male, 70+

Biomarkers: EGFR mutation not detected; BRAF mutation not detected; ALK rearrangement not detected

The cancer progressed after chemoradiation. Atezolizumab was stopped because of pneumonitis, and he later began pemetrexed after a right adrenal mass became highly suspicious for malignancy.

PubMed CentralRead more →

Durable brain and leptomeningeal response to pembrolizumab in Stage IV lung cancer

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: PD-L1 high positive; EGFR negative; BRAF negative; KRAS negative; ROS1 negative; ALK negative

Metastatic Site: right adrenal gland, left sixth rib, brain,…

After 29 pembrolizumab cycles over 20 months, imaging showed no leptomeningeal disease, resolution of 3 brain lesions and marked reduction of the dominant frontal lesion; she remained neurologically intact and radiographically stable.

PubMed CentralRead more →

Stage IIIB Squamous Lung Cancer With Fatal Pembrolizumab Pneumonitis

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: PD-L1 60%; EGFR negative

She died from severe treatment-related pneumonitis after declining further immunosuppression.

PubMed CentralRead more →

Metastatic Lung Adenocarcinoma Complicated by Severe Nivolumab Pneumonitis

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: Microsatellite stable; low tumor mutation burden; PD-L1 70%

His severe nivolumab-related pneumonitis improved after infliximab.

PubMed CentralRead more →

Delayed Adrenal Insufficiency After Nivolumab for Stage IV Lung Cancer

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR unmutated; ALK unmutated; ROS1 unmutated

His weakness, fatigue, weight loss, and orthostatic hypotension resolved after hormone replacement, and he returned home independently.

PubMed CentralRead more →

Autoimmune hemolytic anemia after 39 cycles of nivolumab for metastatic lung cancer

Patient Info: Anonymized, Male, 70+ | Stage IV

Metastatic Site: liver, bone

While nivolumab remained on hold, his lung cancer was stable on imaging and clinically, and hemoglobin had recovered to 14.6 g/dL about 4 months after high-dose prednisone and rituximab began.

PubMed CentralRead more →

Metastatic lung adenocarcinoma causing sudden hearing loss and vertigo

Patient Info: Anonymized, Female, 60s | Stage IV

Metastatic Site: bone|liver|brain|internal auditory meatus

About 10 months after the metastatic diagnosis, she developed new left-sided deafness, vertigo and facial weakness associated with metastatic involvement of the internal auditory meatus.

PubMed CentralRead more →

Stage IV Squamous Lung Cancer Resected After Response to Checkpoint Immunotherapy

Patient Info: Anonymized, male, 50s | Stage IV

After complete resection, he was alive, disease free and off treatment at postoperative follow-up.

PubMed CentralRead more →

Stage III Lung Adenocarcinoma Resected After Chemotherapy and Checkpoint Immunotherapy

Patient Info: Anonymized, female, 60s | Stage III

After complete resection, she was alive, disease free and off treatment at postoperative follow-up.

PubMed CentralRead more →

Metastatic Large Cell Neuroendocrine Lung Cancer With No Residual Tumor After Immunotherapy and Surgery

Patient Info: Anonymized, male, 50s

Surgical pathology showed fibrosis with no residual cancer, and he remained alive, disease free and off treatment at postoperative follow-up.

PubMed CentralRead more →

Oligometastatic Lung Cancer With Brain Spread, Surgery and Later Recurrence

Patient Info: Anonymized, male, 60s | Stage IV

Metastatic Site: brain

After 15 months off treatment he developed mediastinal nodal and distant metastases and was alive with disease on platinum-based chemotherapy 25 months after surgery.

PubMed CentralRead more →

Metastatic Lung Cancer With Adrenal Spread and No Residual Tumor After Immunotherapy and Surgery

Patient Info: Anonymized, female, 50s

Final lung pathology showed no residual viable cancer, and she remained alive, disease free and off treatment at postoperative follow-up.

PubMed CentralRead more →

Finding Happiness Despite Stage IV Lung Cancer

Patient Info: Anonymized, 50s | Stage IV

More than a year after diagnosis, she remained in treatment for Stage IV lung cancer, with some therapies losing effectiveness as the cancer developed resistance.

Dana-FarberRead more →